Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | PYGL | P06737 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.52 |
| ▸ | PYGM | P11217 | 1/20 | 0.52 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.52 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272613 | 0.94 | LMNA (0.56) | MPOGAAPYGLRXFP1AKR1C3 | |
| SCHEMBL2272432 | 0.92 | PYGL (0.55) | MPOPYGLGRIK1MAPK14PYGM | |
| SCHEMBL2275706 | 0.91 | SERPINE1 (0.58) | MPOPYGLMAPK14HPSEPYGM | |
| SCHEMBL2269112 | 0.87 | ACLY (0.59) | PYGLRXFP1HPSEPYGMKCNK2 | |
| SCHEMBL2271588 | 0.86 | SERPINE1 (0.64) | PYGLGRIK1HPSEPYGM | |
| SCHEMBL2269841 | 0.86 | IGF2BP2 (0.61) | PYGLGRIK1MAPK14HPSEPYGM | |
| SCHEMBL2274737 | 0.85 | AVPR2 (0.49) | PYGLRXFP1GRIK1AKR1C3AKR1C2 | |
| SCHEMBL2269555 | 0.84 | HPSE (0.55) | PYGLGRIK1HPSEPYGM | |
| SCHEMBL2274009 | 0.83 | IGF2BP2 (0.61) | PYGLGRIK1MAPK14HPSEPYGM | |
| SCHEMBL2271920 | 0.83 | SERPINE1 (0.57) | PYGLGRIK1AKR1C3AKR1C2HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101094829-B | novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO.,LTD. (JP) | 2012-02-08 | — | — | CN | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | MPO 66/4885GAA 2590/4885PYGL 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.